menu
    • menu
    [{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX-1\/COX2","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX-1\/COX2","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Virpax Pharmaceuticals \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"MMJ International Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MMJ-002","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"MMJ International Holding","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MMJ International Holding \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MMJ International Holding \/ Inapplicable"},{"orgOrder":0,"company":"Arugula Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SIG002","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Arugula Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Arugula Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Arugula Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-001","moa":"CD20","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PDA-002","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"Epic Bio","sponsor":"SOLVE FSHD","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"EPI-321","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Epic Bio \/ SOLVE FSHD","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/ SOLVE FSHD"},{"orgOrder":0,"company":"Epicrispr Biotechnologies","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series B Financing","leadProduct":"EPI-321","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epicrispr Biotechnologies","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.070000000000000007,"dosageForm":"Intravenous Injection","sponsorNew":"Epicrispr Biotechnologies \/ Ally Bridge Group","highestDevelopmentStatusID":"5","companyTruncated":"Epicrispr Biotechnologies \/ Ally Bridge Group"},{"orgOrder":0,"company":"Epic Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EPI-321","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Epic Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/ Inapplicable"},{"orgOrder":0,"company":"Epic Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EPI-321","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Epic Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"DMPK","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avidity Biosciences \/ RTW Investments","highestDevelopmentStatusID":"5","companyTruncated":"Avidity Biosciences \/ RTW Investments"},{"orgOrder":0,"company":"GQ Bio Therapeutics","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"GQ-501","moa":"PRG4","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"GQ Bio Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.029999999999999999,"dosageForm":"Intra-articular Injection","sponsorNew":"GQ Bio Therapeutics \/ Pacira BioSciences","highestDevelopmentStatusID":"5","companyTruncated":"GQ Bio Therapeutics \/ Pacira BioSciences"},{"orgOrder":0,"company":"MiMedx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Micronized Dehydrated Human Amnion Chorion Membrane","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"MiMedx \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MiMedx \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX-1\/COX2","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Film","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Diclofenac","moa":"COX-1\/COX2","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Film","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Celavet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OK100 Stem Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Celavet","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celavet \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Celavet \/ Inapplicable"}]

    Find FDA Investigational New Drug (IND) Submissions for Musculoskeletal

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Epicrispr Biotechnologies

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Epicrispr Biotechnologies

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EPI-321

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : Ally Bridge Group

                            Deal Size : $68.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Epicrispr Secures $68M Series B to Advance FSHD Epigenetic Therapy Trial

                            Details : The financing aims to fund the clinical development of lead program, EPI-321. It is being evaluated for the treatment of facioscapulohumeral muscular dystrophy.

                            Product Name : EPI-321

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 26, 2025

                            Lead Product(s) : EPI-321

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : Ally Bridge Group

                            Deal Size : $68.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GQ Bio Therapeutics

                            Germany arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            GQ Bio Therapeutics

                            Germany arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GQ-501

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : Pacira BioSciences

                            Deal Size : $32.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio

                            Details : Through the acquisition, Pacira will leverage musculoskeletal portfolio, which includes GQ-501 is a helper-dependent adenoviral vector expressing proteoglycan 4 & being developed for osteoarthritis.

                            Product Name : GQ-501

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $18.0 million

                            February 27, 2025

                            Lead Product(s) : GQ-501

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : Pacira BioSciences

                            Deal Size : $32.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MMJ International Holding

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            MMJ International Holding

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MMJ-002

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DEA Continues to Block MMJ Marijuana Drug Development for Neurological Disorder

                            Details : MMJ-002 is a novel cannabis-derived medication, being investigated for the treatment of chorea associated with Huntington's disease (HD).

                            Product Name : MMJ-002

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 10, 2024

                            Lead Product(s) : MMJ-002

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Adicet Bio

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Adicet Bio

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADI-001

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adicet Bio Announces FDA Clearance To Evaluate ADI-001 in Inflammatory Myopathy

                            Details : FDA has agreed to an amendment to the company’s investigational new drug (IND) application to evaluate ADI-001 in idiopathic inflammatory myopathy (IIM) and stiff person syndrome.

                            Product Name : ADI-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            October 16, 2024

                            Lead Product(s) : ADI-001

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Celularity

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Celularity

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PDA-002

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Celularity Requests U.S. FDA ODD for PDA-002 in Muscular Dystrophy Treatment

                            Details : PDA-002 is a placenta-derived mesenchymal-like adherent stromal cell therapy, which is being evaluated for the treatment of facioscapulohumeral muscular dystrophy.

                            Product Name : PDA-002

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 20, 2024

                            Lead Product(s) : PDA-002

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARO-DUX4

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Faciosc...

                            Details : ARO-DUX4 is an investigational RNAi therapeutic designed to reduce expression of the gene that encodes the human double homeobox 4 (DUX4) protein as a potential treatment for FSHD.

                            Product Name : ARO-DUX4

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 17, 2023

                            Lead Product(s) : ARO-DUX4

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Epic Bio

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Epic Bio

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EPI-321

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : SOLVE FSHD

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            SOLVE FSHD Invests in Epic Bio for The Development of A Novel Treatment for Facioscapulohumeral Muscular Dystr...

                            Details : The investment will support development of Epic’s lead program EPI-321, a novel therapeutic that is designed to correct the epigenetic alterations in the D4Z4 region of chromosome 4.

                            Product Name : EPI-321

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 18, 2023

                            Lead Product(s) : EPI-321

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : SOLVE FSHD

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Arugula Sciences

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Arugula Sciences

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIG002

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Arugula Sciences Announces FDA Approval to Proceed with Phase 1 Study of SIG002, a Perinatal-derived Secretome...

                            Details : SIG002 consists purified secretome free of tissue fragments and cells. SIG002 has demonstrated immunoregulatory properties relevant to address the degenerative inflammatory processes involved in osteoarthritis disease etiology.

                            Product Name : SIG002

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 31, 2023

                            Lead Product(s) : SIG002

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            FSD Pharma

                            Canada arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            FSD Pharma

                            Canada arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Palmitoylethanolamide

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain As...

                            Details : FSD201 is a proprietary formulation of ultra-micronized palmitoylethanolamide (PEA). FSD Pharma’s successfully completed Phase 1 clinical trial showed FSD201 to be safe and well tolerated.

                            Product Name : FSD201

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 09, 2022

                            Lead Product(s) : Palmitoylethanolamide

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : Kindeva Drug Delivery

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Virpax Pharmaceuticals Selects Kindeva Drug Delivery as Development Partner for Diclofenac pMDI Commercializat...

                            Details : Epoladerm™ (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee.

                            Product Name : Epoladerm

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 27, 2022

                            Lead Product(s) : Diclofenac

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : Kindeva Drug Delivery

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth